

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
13 January 2005 (13.01.2005)

PCT

(10) International Publication Number  
**WO 2005/003137 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 491/044**,  
A61K 31/407

**FELING, Robert, H., R.** [DE/DE]; Dotzheimerstrasse  
19, D-65185 Wiesbaden (DE).

(21) International Application Number:  
PCT/US2004/019453

(74) Agent: **HAILE, Lisa, A.**; Gray Gary Ware & Friedenrich  
LLP, Suite 1600, 4365 Executive Drive, Suite 1100, San  
Diego, CA 92121-2133 (US).

(22) International Filing Date: 18 June 2004 (18.06.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
10/600,854 20 June 2003 (20.06.2003) US  
10/838,157 30 April 2004 (30.04.2004) US

(81) Designated States (*unless otherwise indicated, for every  
kind of national protection available*): AE, AG, AL, AM,  
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US (patent), UZ, VC, VN, YU,  
ZA, ZM, ZW.

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier applications:  
US 10/600,854 (CON)  
Filed on 20 June 2003 (20.06.2003)  
US 10/838,157 (CON)  
Filed on 30 April 2004 (30.04.2004)

(84) Designated States (*unless otherwise indicated, for every  
kind of regional protection available*): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **THE  
REGENTS OF THE UNIVERSITY OF CALIFORNIA**  
[US/US]; 1111 Franklin Street, Fifth Floor, Oakland, CA  
94607-5200 (US).

**Published:**

- *with international search report*
- *before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **FENICAL,  
William, H.** [US/US]; 1128 Highland Drive, Del Mar, CA  
92014 (US). **JENSEN, Paul, R.** [US/US]; 1706 Bancroft  
Street, San Diego, CA 92102 (US). **MINCER, Tracy, J.**  
[US/US]; 3822 First Avenue, San Diego, CA 92103 (US).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: **SALINOSPORAMIDES AND METHODS FOR USE THEREOF**

(57) Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet *Salinospora* has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC<sub>50</sub> values, high pharmaceutical potency, and selectivity for cancer cells over fungi.

WO 2005/003137 A1

## **SALINOSPORAMIDES AND METHODS FOR USE THEREOF**

### **CROSS REFERENCE TO RELATED APPLICATIONS**

[0001] This application claims priority from U.S. Application Serial No. 10/838,157, filed April 30, 2004, and from U.S. Application Serial No. 10/600,854 filed June 20, 2003, both entitled "Salinosporamides and Methods for Use Thereof."

### **GRANT INFORMATION**

[0002] This invention was made in part with government support under Grant No. CA44848 awarded by the National Institutes of Health, National Cancer Institute. The United States government may have certain rights in this invention.

### **BACKGROUND OF THE INVENTION**

#### **FIELD OF THE INVENTION**

[0003] The invention relates generally to anti-neoplastic agents, and more particularly to salinosporamides and their use as anti-neoplastic agents.

#### **BACKGROUND INFORMATION**

[0004] Neoplastic diseases, characterized by the proliferation of cells not subject to the normal control of cell growth, are a major cause of death in humans. Clinical experience in chemotherapy has demonstrated that new and more effective cytotoxic drugs are desirable to treat these diseases. Indeed, the use of anti-neoplastic agents has increased due to the identification of new neoplasms and cancer cell types with metastases to different areas, and due to the effectiveness of antineoplastic treatment protocols as a primary and adjunctive medical treatment for cancer.

[0005] Since anti-neoplastic agents are cytotoxic (poisonous to cells) they not only interfere with the growth of tumor cells, but those of normal cells. Anti-neoplastic agents have more of an effect on tumor cells than normal cells because of their rapid growth. Thus, normal tissue cells that are affected by anti-neoplastic agents are rapidly dividing


cells, such as bone marrow (seen in low blood counts), hair follicles (seen by way of hair loss) and the GI mucosal epithelium (accounting for nausea, vomiting, loss of appetite, diarrhea). In general, anti-neoplastic agents have the lowest therapeutic indices of any class of drugs used in humans and hence produce significant and potentially life-threatening toxicities. Certain commonly-used anti-neoplastic agents have unique and acute toxicities for specific tissues. For example, the vinca alkaloids possess significant toxicity for nervous tissues, while adriamycin has specific toxicity for heart tissue and bleomycin has for lung tissue.

[0006] Thus, there is a continuing need for anti-neoplastic agents that are effective in inhibiting the proliferation of hyperproliferative cells while also exhibiting  $IC_{50}$  values lower than those values found for current anti-neoplastic agents, thereby resulting in marked decrease in potentially serious side effects.

#### SUMMARY OF THE INVENTION

[0007] The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet *Salinospora* has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low  $IC_{50}$  values, high pharmaceutical potency, and selectivity for cancer cells over fungi.

[0008] In one embodiment of the invention, there is provided compounds having the structure (I):



wherein:


$R_1$  to  $R_3$  are each independently  $-H$ , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl,  $-C(O)H$ , acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl;

Each  $R_4$  is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl;

$E_1$  to  $E_4$  are each independently  $-O$ ,  $-NR_5$ , or  $-S$ , wherein  $R_5$  is  $-H$  or  $C_1$ - $C_6$  alkyl; and

$x$  is 0 to 8.

[0009] In a further embodiment of the invention, there are provided compounds having the structure (II):



II

wherein:


$R_1$  to  $R_3$  are each independently  $-H$ , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl,  $-C(O)H$ , acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfonyl;

Each  $R_4$  is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl;

$E_1$  to  $E_4$  are each independently  $-O$ ,  $-NR_5$ , or  $-S$ , wherein  $R_5$  is  $-H$  or  $C_1$ - $C_6$  alkyl; and

$x$  is 0 to 8.

[0010] In another embodiment of the invention, there are provided compounds having the structure (III):



III

wherein:


R<sub>1</sub> to R<sub>3</sub> are each independently -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfonyl,

each R<sub>4</sub> is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl,

E<sub>1</sub> to E<sub>4</sub> are each independently -O, -NR<sub>5</sub>, or -S, wherein R<sub>5</sub> is -H or C<sub>1</sub>-C<sub>6</sub> alkyl, and


x is 0 to 8.

[0011] In still a further embodiment of the invention, there are provided compounds having the structure (IV):




IV

[0012] In a further embodiment of the invention, there are provided compounds having the structure (V):



V

[0013] In a further embodiment of the invention, there are provided compounds having the structure (VI):



VI

[0014] In another embodiment, there are provided pharmaceutical compositions including at least one compound of structures I-VI in a pharmaceutically acceptable carrier therefor.

[0015] In another embodiment, there are provided articles of manufacture including packaging material and a pharmaceutical composition contained within the packaging material, wherein the packaging material includes a label which indicates that the pharmaceutical composition can be used for treatment of cell proliferative disorders and wherein the pharmaceutical composition includes at least one compound of structures I-VI.

[0016] In yet another embodiment, there are provided methods for treating a mammalian cell proliferative disorder. Such a method can be performed for example, by administering to a subject in need thereof a therapeutically effective amount of a compound having structures I-VI.

[0017] In an additional embodiment, there are provided methods for producing a compound of structures I-VI having the ability to inhibit the proliferation of hyperproliferative mammalian cells. Such a method can be performed, for example, by



cultivating a culture of a *Salinospora* sp. strains CNB392 (ATCC # \_\_\_\_\_) or CNB476 (ATCC PTA-5275) and isolating from the culture at least one compound of structure I.

### BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 depicts the chemical structure of an exemplary compound of the invention, Salinosporamide A, with relative stereochemistry.

[0019] Figure 2 depicts a phylogenetic tree illustrating the phylogeny of "*Salinospora*".

[0020] Figure 3 depicts the chemical structure of Etoposide, an anti-neoplastic agent in therapy against several human cancers.

[0021] Figure 4 compares the cytotoxic activity and dose response curves of Salinosporamide A and Etoposide.

[0022] Figure 5 is a block diagram depicting an exemplary separation scheme used to isolate Salinosporamide A.

[0023] Figures 6-14 set forth NMR, IR, and UV spectroscopic data used to elucidate the structure of Salinosporamide A.


[0024] Figure 15 sets forth the signature nucleotides that strains CNB392 and CNB476 possess within their 16S rDNA, which separate these strains phylogenetically from all other family members of the family Micromonosporaceae.

[0025] Figure 16 depicts the chemical structure of an exemplary compound of the invention, salinosporamide A (structure V), with absolute stereochemistry.

[0026] Figure 17 ORTEP plot of the final X-ray structure of salinosporamide A, depicting the absolute stereochemistry.

## DETAILED DESCRIPTION OF THE INVENTION

[0027] In one embodiment, there are provided compounds having the structure (I):



wherein:


$R_1$  to  $R_3$  are each independently -H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl, -C(O)H, acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl;

Each  $R_4$  is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl;

$E_1$  to  $E_4$  are each independently -O, -NR<sub>5</sub>, or -S, wherein  $R_5$  is -H or C<sub>1</sub>-C<sub>6</sub> alkyl; and

$x$  is 0 to 8.

[0028] In a further embodiment of the invention, there are provided compounds having the structure (II):



II

wherein:


$R_1$  to  $R_3$  are each independently  $-H$ , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl,  $-C(O)H$ , acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl;

Each  $R_4$  is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl;

$E_1$  to  $E_4$  are each independently  $-O$ ,  $-NR_5$ , or  $-S$ , wherein  $R_5$  is  $-H$  or  $C_1$ - $C_6$  alkyl; and

$x$  is 0 to 8.

[0029] In one embodiment, there are provided compounds having the structure (III):



III

wherein:


$R_1$  to  $R_3$  are each independently  $-H$ , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl,  $-C(O)H$ , acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfonyl,

each  $R_4$  is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl,

$E_1$  to  $E_4$  are each independently  $-O$ ,  $-NR_5$ , or  $-S$ , wherein  $R_5$  is  $-H$  or  $C_1$ - $C_6$  alkyl, and


$x$  is 0 to 8.

[0030] In still a further embodiment of the invention, there are provided compounds having the structure (IV):




IV

[0031] In a further embodiment of the invention, there are provided compounds having the structure (V):



V

[0032] In a further embodiment of the invention, there are provided compounds having the structure (VI):



VI

[0033] As used herein, the term "alkyl" refers to a monovalent straight or branched chain hydrocarbon group having from one to about 12 carbon atoms, including methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, and the like.

[0034] As used herein, "substituted alkyl" refers to alkyl groups further bearing one or more substituents selected from hydroxy, alkoxy, mercapto, cycloalkyl, substituted cycloalkyl, heterocyclic, substituted heterocyclic, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryloxy, substituted aryloxy, halogen, cyano, nitro, amino, amido, -C(O)H, acyl, oxyacyl, carboxyl, sulfonyl, sulfonamide, sulfuryl, and the like.

[0035] As used herein, "lower alkyl" refers to alkyl groups having from 1 to about 6 carbon atoms.

[0036] As used herein, "alkenyl" refers to straight or branched chain hydrocarbyl groups having one or more carbon-carbon double bonds, and having in the range of about 2 up to 12 carbon atoms, and "substituted alkenyl" refers to alkenyl groups further bearing one or more substituents as set forth above.

[0037] As used herein, "alkynyl" refers to straight or branched chain hydrocarbyl groups having at least one carbon-carbon triple bond, and having in the range of about 2

up to 12 carbon atoms, and "substituted alkynyl" refers to alkynyl groups further bearing one or more substituents as set forth above.

[0038] As used herein, "aryl" refers to aromatic groups having in the range of 6 up to 14 carbon atoms and "substituted aryl" refers to aryl groups further bearing one or more substituents as set forth above.

[0039] As used herein, "heteroaryl" refers to aromatic rings containing one or more heteroatoms (e.g., N, O, S, or the like) as part of the ring structure, and having in the range of 3 up to 14 carbon atoms and "substituted heteroaryl" refers to heteroaryl groups further bearing one or more substituents as set forth above.

[0040] As used herein, "alkoxy" refers to the moiety -O-alkyl-, wherein alkyl is as defined above, and "substituted alkoxy" refers to alkoxy groups further bearing one or more substituents as set forth above.

[0041] As used herein, "thioalkyl" refers to the moiety -S-alkyl-, wherein alkyl is as defined above, and "substituted thioalkyl" refers to thioalkyl groups further bearing one or more substituents as set forth above.

[0042] As used herein, "cycloalkyl" refers to ring-containing alkyl groups containing in the range of about 3 up to 8 carbon atoms, and "substituted cycloalkyl" refers to cycloalkyl groups further bearing one or more substituents as set forth above.

[0043] As used herein, "heterocyclic", refers to cyclic (i.e., ring-containing) groups containing one or more heteroatoms (e.g., N, O, S, or the like) as part of the ring structure, and having in the range of 3 up to 14 carbon atoms and "substituted heterocyclic" refers to heterocyclic groups further bearing one or more substituents as set forth above.

[0044] In certain embodiments, there are provided compounds of structures I-III wherein E<sub>1</sub>, E<sub>3</sub>, and E<sub>4</sub> are -O, and E<sub>2</sub> is -NH.

[0045] In certain embodiments, there are provided compounds of structures I-III wherein R<sub>1</sub> and R<sub>2</sub> are -H, alkyl, or substituted alkyl, and R<sub>3</sub> is hydroxy or alkoxy. In some embodiments, R<sub>1</sub> is substituted alkyl. Exemplary substituted alkyls contemplated for use include halogenated alkyls, such as for example chlorinated alkyls.


[0046] The compounds of the invention may be formulated into pharmaceutical compositions as natural or salt forms. Pharmaceutically acceptable non-toxic salts include the base addition salts (formed with free carboxyl or other anionic groups) which may be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino-ethanol, histidine, procaine, and the like. Such salts may also be formed as acid addition salts with any free cationic groups and will generally be formed with inorganic acids such as, for example, hydrochloric, sulfuric, or phosphoric acids, or organic acids such as acetic, p-toluenesulfonic, methanesulfonic acid, oxalic, tartaric, mandelic, and the like. Salts of the invention include amine salts formed by the protonation of an amino group with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like. Salts of the invention also include amine salts formed by the protonation of an amino group with suitable organic acids, such as p-toluenesulfonic acid, acetic acid, and the like. Additional excipients which are contemplated for use in the practice of the present invention are those available to those of ordinary skill in the art, for example, those found in the United States Pharmacopeia Vol. XXII and National Formulary Vol. XVII, U.S. Pharmacopeia Convention, Inc., Rockville, MD (1989), the relevant contents of which is incorporated herein by reference.

[0047] The compounds according to this invention may contain one or more asymmetric carbon atoms and thus occur as racemates and racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. The term "stereoisomer" refers to chemical compounds which differ from each other only in the way that the different groups in the molecules are oriented in space. Stereoisomers have the same molecular weight, chemical composition, and constitution as another, but with the atoms grouped differently. That is, certain identical chemical moieties are at different orientations in space and, therefore, when pure, have the ability to rotate the plane of polarized light. However, some pure stereoisomers may have an optical rotation that is so slight that it is undetectable with present instrumentation. All such isomeric forms of these compounds are expressly included in the present invention.



[0048] Each stereogenic carbon may be of R or S configuration. Although the specific compounds exemplified in this application may be depicted in a particular configuration, compounds having either the opposite stereochemistry at any given chiral center or mixtures thereof are also envisioned. When chiral centers are found in the derivatives of this invention, it is to be understood that this invention encompasses all possible stereoisomers. The terms "optically pure compound" or "optically pure isomer" refers to a single stereoisomer of a chiral compound regardless of the configuration of the compound.

[0049] Exemplary invention compounds of structure I are shown below:



[0050] Salinosporamide A exhibits a molecular structure having a variety of functional groups (lactone, alkylhalide, amide, hydroxide) that can be chemically modified to produce synthetic derivatives. Accordingly, exemplary invention compound Salinosporamide A provides an excellent lead structure for the development of synthetic and semisynthetic derivatives. Indeed, Salinosporamide A can be derivatized to improve pharmacokinetic and pharmacodynamic properties, which facilitate administration and increase utility of the derivatives as anti-neoplastic agents. Procedures for chemically modifying invention salinosporamide compounds to produce additional compounds within the scope of the present invention are available to those of ordinary skill in the art.

[0051] Salinosporamide A shows strong cytotoxic activity against human colon cancer cells in the HTC-116 cell assays. The  $IC_{50}$  of 11 ng/mL exceeds the activity of etoposide (see Figure 3,  $IC_{50}$  828 ng/mL), an anticancer drug used for treatment of a number of cancers, by almost two orders of magnitude (see Figure 4). This high activity makes invention salinosporamides excellent candidates for use in the treatment of various human cancers, especially slow growing, refractile cancers for which there are no therapies. Salinosporamide A is specific to inhibition of mammalian cells and shows little antifungal activity against *Candida albicans* ( $IC_{50}$  250  $\mu$ g/mL) and no antibacterial activity (*Staphylococcus aureus*, *Enterococcus faecium*). The  $IC_{50}$  of Salinosporamide A is far lower than the strongest chemotherapeutic agents currently in use or in clinical trials.

[0052] Salinosporamide A is a fermentation product of the marine actinomycete strains CNB392 and CNB476. These strains are members of the order Actinomycetales, which are high G + C gram positive bacteria. The novelty of CNB392 and CNB476 is at the genus level. Invention compounds set forth herein are produced by certain "*Salinosporea*" sp. In some embodiments, invention compounds are produced by "*Salinosporea*" sp. strains CNB392 and CNB476. To that end, the CNB392 and CNB476 strains of "*Salinosporea*" sp. were deposited on June 20, 2003, pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852 U.S.A. under ATCC Accession Nos. \_\_\_\_\_ and PTA-5275, respectively.

[0053] As is the case with other organisms, the characteristics of "*Salinosporea*" sp. are subject to variation. For example, recombinants, variants, or mutants of the specified strain may be obtained by treatment with various known physical and chemical mutagens, such as ultraviolet ray, X-rays, gamma rays, and N-methyl-N'-nitro-N-nitrosoguanidine. All natural and induced variants, mutants, and recombinants of the specified strain which retain the characteristic of producing a compound of the invention are intended to be within the scope of the claimed invention.

[0054] Invention compounds can be prepared, for example, by bacterial fermentation, which generates the compounds in sufficient amounts for pharmaceutical drug

development and for clinical trials. In some embodiments, invention compounds are produced by fermentation of the actinomycete strains CNB392 and CNB476 in A1Bfe+C or CKA-liquid media. Essential trace elements which are necessary for the growth and development of the culture should also be included in the culture medium. Such trace elements commonly occur as impurities in other constituents of the medium in amounts sufficient to meet the growth requirements of the organisms. It may be desirable to add small amounts (i.e. 0.2 mL/L) of an antifoam agent such as polypropylene glycol (M.W. about 2000) to large scale cultivation media if foaming becomes a problem. The organic metabolites are isolated by adsorption onto an amberlite XAD-16 resin. For example, Salinosporamide A is isolated by elution of the XAD-16 resin with methanol:dichloromethane 1:1, which affords about 105 mg crude extract per liter of culture. Salinosporamide A is then isolated from the crude extract by reversed-phase flash chromatography followed by reverse-phase HPLC and normal phase HPLC, which yields 6.7 mg of Salinosporamide A. Figure 5 sets forth a block diagram outlining isolation and separation protocols for invention compounds.

[0055] The structure of Salinosporamide A was elucidated by a variety of NMR techniques, mass spectroscopy, IR, and UV spectroscopy, as set forth in Figures 6-14.

[0056] The absolute structure of salinosporamide A, and confirmation of the overall structure of salinosporamide A, was achieved by single-crystal X-ray diffraction analysis (see Example 3).

[0057] The present invention also provides articles of manufacture including packaging material and a pharmaceutical composition contained within the packaging material, wherein the packaging material comprises a label which indicates that the pharmaceutical composition can be used for treatment of disorders and wherein the pharmaceutical composition includes a compound according to the present invention. Thus, in one aspect, the invention provides a pharmaceutical composition including a compound of the invention, wherein the compound is present in a concentration effective to treat cell proliferative disorders. The concentration can be determined by one of skill in the art according to standard treatment regimen or as determined by an in vivo animal assay, for example.

[0058] Pharmaceutical compositions employed as a component of invention articles of manufacture can be used in the form of a solid, a solution, an emulsion, a dispersion, a micelle, a liposome, and the like, wherein the resulting composition contains one or more invention compounds as an active ingredient, in admixture with an organic or inorganic carrier or excipient suitable for enteral or parenteral applications. Compounds employed for use as a component of invention articles of manufacture may be combined, for example, with the usual non-toxic, pharmaceutically acceptable carriers for tablets, pellets, capsules, suppositories, solutions, emulsions, suspensions, and any other form suitable for use. The carriers which can be used include glucose, lactose, gum acacia, gelatin, mannitol, starch paste, magnesium trisilicate, talc, corn starch, keratin, colloidal silica, potato starch, urea, medium chain length triglycerides, dextrans, and other carriers suitable for use in manufacturing preparations, in solid, semisolid, or liquid form. In addition auxiliary, stabilizing, thickening and coloring agents and perfumes may be used.

[0059] The compositions of the present invention may contain other therapeutic agents as described below, and may be formulated, for example, by employing conventional solid or liquid vehicles or diluents, as well as pharmaceutical additives of a type appropriate to the mode of desired administration (for example, excipients, binders, preservatives, stabilizers, flavors, etc.) according to techniques such as those well known in the art of pharmaceutical formulation.

[0060] Invention pharmaceutical compositions may be administered by any suitable means, for example, orally, such as in the form of tablets, capsules, granules or powders; sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular, or intracisternal injection or infusion techniques (e.g., as sterile injectable aqueous or non-aqueous solutions or suspensions); nasally such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally such as in the form of suppositories; in dosage unit formulations containing non-toxic, pharmaceutically acceptable vehicles or diluents. Invention compounds may, for example, be administered in a form suitable for immediate release or extended release. Immediate release or extended release may be achieved by the use of suitable pharmaceutical compositions comprising invention compounds, or, particularly in the case of extended release, by the use of devices such as

subcutaneous implants or osmotic pumps. Invention compounds may also be administered liposomally.

[0061] The invention further provides methods for using invention salinosporamide compounds of structures (I)-(VI) to inhibit the proliferation of mammalian cells by contacting these cells with an invention salinosporamide compound in an amount sufficient to inhibit the proliferation of the mammalian cell. One embodiment is a method to inhibit the proliferation of hyperproliferative mammalian cells. For purposes of this invention, "hyperproliferative mammalian cells" are mammalian cells which are not subject to the characteristic limitations of growth, e.g., programmed cell death (apoptosis). A further preferred embodiment is when the mammalian cell is human. The invention further provides contacting the mammalian cell with at least one invention salinosporamide compound and at least one additional anti-neoplastic agent.

[0062] In another embodiment, there are provided methods for treating a mammalian cell proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of structures (I)-(VI). Cell proliferative disorders that can be effectively treated by the methods of the invention include disorders characterized by the formation of neoplasms. As such, invention compounds are anti-neoplastic agents. As used herein, "neoplastic" pertains to a neoplasm, which is an abnormal growth, such growth occurring because of a proliferation of cells not subject to the usual limitations of growth. As used herein, "anti-neoplastic agent" is any compound, composition, admixture, co-mixture or blend which inhibits, eliminates, retards or reverses the neoplastic phenotype of a cell. In certain embodiments, the neoplasms are selected from mammary, small-cell lung, non-small-cell lung, colorectal, leukemia, melanoma, pancreatic adenocarcinoma, central nervous system (CNS), ovarian, prostate, sarcoma of soft tissue or bone, head and neck, gastric which includes thyroid and non-Hodgkin's disease, stomach, myeloma, bladder, renal, neuroendocrine which includes thyroid and non-Hodgkin's disease and Hodgkin's disease neoplasms. In one embodiment, the neoplasms are colorectal.

[0063] Chemotherapy, surgery, radiation therapy, therapy with biologic response modifiers, and immunotherapy are currently used in the treatment of cancer. Each mode

of therapy has specific indications which are known to those of ordinary skill in the art, and one or all may be employed in an attempt to achieve total destruction of neoplastic cells. Chemotherapy utilizing one or more invention salinosporamide compounds is provided by the present invention. Moreover, combination chemotherapy, chemotherapy utilizing invention salinosporamide compounds in combination with other neoplastic agents, is also provided by the invention as combination therapy is generally more effective than the use of single anti-neoplastic agents. Thus, a further aspect of the present invention provides compositions containing a therapeutically effective amount of at least one invention salinosporamide compound in combination with at least one other anti-neoplastic agent. Such compositions can also be provided together with physiologically tolerable liquid, gel or solid carriers, diluents, adjuvants and excipients. Such carriers, diluents, adjuvants and excipients may be found in the United States Pharmacopeia Vol. XXII and National Formulary Vol XVII, U.S. Pharmacopeia Convention, Inc., Rockville, Md. (1989), the contents of which are herein incorporated by reference. Additional modes of treatment are provided in AHFS Drug Information, 1993 ed. by the American Hospital Formulary Service, pp. 522-660, the contents of which are herein incorporated by reference.

[0064] Anti-neoplastic agents which may be utilized in combination with an invention salinosporamide compound include those provided in The Merck Index, 11th ed. Merck & Co., Inc. (1989) pp. Ther 16-17, the contents of which are hereby incorporated by reference. In a further embodiment of the invention, anti-neoplastic agents may be antimetabolites which may include, but are not limited to, methotrexate, 5-fluorouracil, 6-mercaptopurine, cytosine arabinoside, hydroxyurea, and 2-chlorodeoxyadenosine. In another embodiment of the present invention, the anti-neoplastic agents contemplated are alkylating agents which may include, but are not limited to, cyclophosphamide, melphalan, busulfan, paraplatin, chlorambucil, and nitrogen mustard. In a further embodiment of the invention, the antineoplastic agents are plant alkaloids which may include, but are not limited to, vincristine, vinblastine, taxol, and etoposide. In a further embodiment of the invention, the anti-neoplastic agents contemplated are antibiotics which may include, but are not limited to, doxorubicin (adriamycin), daunorubicin, mitomycin c, and bleomycin. In a further embodiment of the invention, the anti-

neoplastic agents contemplated are hormones which may include, but are not limited to, calusterone, diomostavolone, propionate, epitiostanol, mepitiothane, testolactone, tamoxifen, polyestradiol phosphate, megestrol acetate, flutamide, nilutamide, and trilotane. In a further embodiment of the invention, the anti-neoplastic agents contemplated include enzymes which may include, but are not limited to, L-Asparaginase or aminoacridine derivatives which may include, but are not limited to, amsacrine. Additional anti-neoplastic agents include those provided in Skeel, Roland T., "Antineoplastic Drugs and Biologic Response Modifier: Classification, Use and Toxicity of Clinically Useful Agents," Handbook of Cancer Chemotherapy (3rd ed.), Little Brown & Co. (1991), the contents of which are herein incorporated by reference.

[0065] In addition to primates, such as humans, a variety of other mammals can be treated according to the method of the present invention. For instance, mammals including, but not limited to, cows, sheep, goats, horses, dogs, cats, guinea pigs, rats or other bovine, ovine, equine, canine, feline, rodent or murine species can be treated.

[0066] The term "therapeutically effective amount" means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician, e.g., lessening of the effects/symptoms of cell proliferative disorders.

[0067] By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

[0068] The terms "administration of" and or "administering a" compound should be understood to mean providing a compound of the invention to the individual in need of treatment. Administration of the invention compounds can be prior to, simultaneously with, or after administration of another therapeutic agent or other anti-neoplastic agent.

[0069] The pharmaceutical compositions for the administration of the compounds of this invention may conveniently be presented in dosage unit form and may be prepared by any of the methods well known in the art of pharmacy. All methods include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients. In general, the pharmaceutical compositions are prepared by

uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases.

[0070] The pharmaceutical compositions containing the active ingredient may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.

[0071] Compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated to form osmotic therapeutic tablets for control release.

[0072] Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.



[0073] Aqueous suspensions contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents may be a naturally-occurring phosphatide, for example lecithin, or condensation products of an alkylene oxide with fatty acids, for example polyoxyethylene stearate, or condensation products of ethylene oxide with long chain aliphatic alcohols, for example heptadecaethyleneoxycetanol, or condensation products of ethylene oxide with partial esters derived from fatty acids and a hexitol such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, for example polyethylene sorbitan monooleate. The aqueous suspensions may also contain one or more preservatives, for example ethyl, or n-propyl, p-hydroxybenzoate, one or more coloring agents, one or more flavoring agents, and one or more sweetening agents, such as sucrose or saccharin.

[0074] Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid.

[0075] Dispersible powders and granules suitable for preparation of an aqueous suspension by the addition of water provide the active ingredient in admixture with a dispersing or wetting agent, suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example sweetening, flavoring and coloring agents, may also be present.

[0076] Syrups and elixirs may be formulated with sweetening agents, for example glycerol, propylene glycol, sorbitol or sucrose. Such formulations may also contain a demulcent, a preservative and flavoring and coloring agents.

[0077] The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents which have been mentioned above. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3-butane diol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid find use in the preparation of injectables.

[0078] The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions can be prepared by mixing the drug with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycols.

[0079] For topical use, creams, ointments, jellies, solutions or suspensions, etc., containing the compounds of the present invention are employed.

[0080] Compounds and compositions of the invention can be administered to mammals for veterinary use, such as for domestic animals, and clinical use in humans in a manner similar to other therapeutic agents. In general, the dosage required for therapeutic efficacy will vary according to the type of use and mode of administration, as well as the particularized requirements of individual hosts. Ordinarily, dosages will range from about 0.001 to 1000  $\mu\text{g/kg}$ , more usually 0.01 to 10  $\mu\text{g/kg}$ , of the host body weight.

Alternatively, dosages within these ranges can be administered by constant infusion over an extended period of time, usually exceeding 24 hours, until the desired therapeutic benefits have been obtained. It will be understood, however, that the specific dose level

and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

[0081] The invention will now be described in greater detail by reference to the following non-limiting examples.

## EXAMPLES

### Methods and Materials

[0082] HPLC-Purification of invention compounds was accomplished by RP-MPLC on C18-solid phase (Aldrich) using a step gradient on Kontes Flex-columns (15 x 7 mm). Semipreparative HPLC was performed on an isocratic HPLC system with a Waters pump 6000H on normal phase column Si-Dynamas-60Å (250 x 5 mm) or reversed phase column C18-Dynamax-60Å, flow 2 mL/minute, with a differential refractometric detector Waters R401.

[0083] LC-MS-The LC-MS chromatography was performed on a Hewlett-Packard system series HP1100 with DAD and MSD1100 detection. The separation was accomplished on reversed phase C18 (Agilent Hypersil ODS 5 µm, column dimension 4.6 x 100 mm), flow rate 0.7 mL/minute using a standard gradient: 10% acetonitrile, 15 minutes; 98% acetonitrile (Burdick & Jackson high purity solvents). The MS-detection was in ESI positive mode, capillary voltage 3500 eV, fragmentation voltage 70 eV, mass range *m/z* 100-1000. The APCI-mode was measured at a flow rate of 0.5 mL/minute, positive detection, capillary voltage 3000 eV, fragmentation voltage 70 eV.

[0084] NMR-NMR spectra were measured on a Varian 300 MHz gradient field spectrometer with inverse-mode for <sup>1</sup>H or 2D-NMR spectra. The <sup>13</sup>C and DEPT spectra were measured on a Varian 400 MHz, broad band instrument. Thereference is set on the internal standard tetramethylsilane (TMS, 0.00 ppm).

[0085] MS-EI-Low resolution MS-EI spectra were performed on a Hewlett-Packard mass spectrometer with magnetic sector field device, heating rate 20°C/minute up to 320°C, direct injection inlet.

[0086] FTMS-MALDI- High resolution MS data were obtained by MALDI operating mode on an IonSpec Ultima FT Mass Spectrometer.

[0087] IR-Infrared spectra were measured on a Perkin-Elmer FT infrared spectrophotometer using NaCl windows.

### Example 1

#### Isolation and Characterization of "*Salinospora*" species, Culture Nos. CNB392 and CNB476

[0088] CNB392 and CNB476 possess signature nucleotides within their 16S rDNA which separate these strains phylogenetically from all other members of the family Micromonosporaceae (see Figure 15) These signature nucleotides have been determined to be a definitive marker for members of this group which also have a physiological growth requirement of sodium. Signature nucleotides were aligned to *E. coli* positions 27-1492 using all existing members of the Micromonosporaceae in the Ribosomal Database Project as of 1-31-01. For the "*Salinospora*" clade, 45 partially sequenced morphotypes displayed all the signature nucleotides from positions 207-468. The seven "*Salinospora*" isolates sequenced almost in their entirety (see Figure 2) displayed all of the signatures in Figure 15.

[0089] The strains CNB392 and CNB476 form bright orange to black colonies on agar and lacks aerial mycelia. Dark brown and bright orange diffusible pigments are produced depending upon cellular growth stage. Spores blacken the colony surface and are borne on substrate mycelia. Vegetative mycelia are finely branched and do not fragment. Spores are produced singly or in clusters. Neither sporangia nor spore motility has been observed for these strains. CNB392 and CNB476 have an obligate growth requirement for sodium and will not grow on typical media used for maintenance of other generic members of the Micromonosporaceae. CNB392 and CNB476 have been found to grow optimally on solid media TCG or M1 at 30°C.

TCG	3 grams tryptone	M1	10 grams starch
	5 grams casitone		4 grams yeast extract
	4 grams glucose		2 grams peptone
	18 grams agar (optional)		18 grams agar (optional)
	1 liter filtered seawater		1 liter filtered seawater

### Fermentation

[0090] CNB392 and CNB476 are cultured in shaken A1Bfe+C or CKA-liquid media, 1 liter at 35°C for 9 days. After 4 days 20 grams Amberlite XAD-16 resin (Sigma, nonionic polymeric adsorbent) is added.

A1Bfe+C	10 grams starch	CKA	5 grams starch
	4 grams yeast extract		4 mL hydrosolubles (50%)
	2 grams peptone		2 grams menhaden meal
	1 gram CaCO <sub>3</sub>		2 grams kelp powder
	5 mL KBr (aqueous solution, 20 grams/liter)		2 grams chitosan
	5 mL Fe <sub>2</sub> (SO <sub>4</sub> ) <sub>3</sub> x 4 H <sub>2</sub> O (8 grams/liter)		1 liter filtered seawater
	1 liter filtered seawater		

### Extraction

[0091] The XAD-16 resin is filtered and the organic extract is eluted with 1 liter ethylacetate followed by 1 liter methanol. The filtrate is then extracted with ethylacetate (3 x 200 mL). The crude extract from the XAD adsorption is 105 mg. Cytotoxicity on the human colon cancer cell HCT-116 assay is IC<sub>50</sub> < 0.076 µg/mL.

### Isolation of Salinosporamide A from CNB392

[0092] The crude extract was flash-chromatographed over C18 reversed phase (RP) using a step gradient (Figure 5). The HCT-116 assay resulted in two active fractions, CNB392-5 and CNB392-6. The combined active fractions (51.7 mg), HCT-116 < 0.076 µg/mL) were then chromatographed on an isocratic RP-HPLC, using 85% methanol at 2 mL/minute flow as eluent and using refractive index detection. The active fraction CNB392-5/6 (7.6 mg, HCT-116 < 0.076 µg/mL) was purified on an isocratic normal

phase HPLC on silica gel with ethyl acetate:isooctane (9:1) at 2 mL/minute.

Salinosporamide A (Figure 1) was isolated as a colorless, amorphous solid in 6.7 mg per 1 liter yield (6.4 %). TLC on silica gel (dichloromethane:methanol 9:1) shows Salinosporamide A at  $r_f = 0.6$ , no UV extinction or fluorescence at 256 nm, yellow with  $H_2SO_4$ /ethanol, dark red-brown with Godin reagent (vanillin/ $H_2SO_4/HClO_4$ ).

Salinosporamide A is soluble in  $CHCl_3$ , methanol, and other polar solvents like DMSO, acetone, acetonitrile, benzene, pyridine, N,N-dimethylformamide, and the like.  $^1H$  NMR: ( $d_5$ -pyridine, 300 MHz) 1.37/1.66 (2H, m,  $CH_2$ ), 1.70/2.29 (2H, m,  $CH_2$ ), 1.91 (2H, broad,  $CH_2$ ), 2.07 (3H, s,  $CH_3$ ), 2.32/2.48 (2H, ddd,  $^3J = 7.0$  Hz,  $CH_2$ ), 2.85 (1H, broad, m, CH), 3.17 (1H, dd,  $^3J = 10$  Hz, CH), 4.01/4.13 (2H, m,  $CH_2$ ), 4.25 (1H, d,  $^3J = 9.0$  Hz, CH), 4.98 (1H, broad, OH), 5.88, (1H, ddd,  $^3J = 10$  Hz, CH), 6.41 (1H, broad d,  $^3J = 10$  Hz, CH) 10.62 (1H, s, NH).

$^{13}C$  NMR/DEPT: ( $d_5$ -pyridine, 400 MHz) 176.4 (COOR), 169.0 (CONH), 128.8 (=CH), 128.4 (=CH), 86.1 ( $C_q$ ), 80.2 ( $C_q$ ), 70.9 (CH), 46.2 (CH), 43.2 ( $CH_2$ ), 39.2 (CH), 29.0 ( $CH_2$ ), 26.5 ( $CH_2$ ), 25.3 ( $CH_2$ ), 21.7 ( $CH_2$ ), 20.0 ( $CH_3$ )

LC-MS (ESI)  $t_r = 10.0$  minutes, flow 0.7 mL/minute

$m/z$ :  $(M+H)^+$  314,  $(M+Na)^+$  336; fragments:  $(M+H-CO_2)^+$  292,  $(M+H-CO_2-H_2O)^+$  270, 252, 204. Cl pattern:  $(M+H, 100\%)^+$  314,  $(M+H, 30\%)^+$  316.

LC MS (APCI):  $t_r = 11.7$  minutes, flow 0.5 mL/minute

$m/z$ :  $(M+H)^+$  314, fragments:  $(M+H-CO_2-H_2O)^+$  270, 252, 232, 216, 160.

Cl pattern:  $(M+H, 100\%)^+$  314,  $(M+H, 30\%)^+$  316.

EI:  $m/z$ : 269, 251, 235, 217, 204, 188 (100%), 160, 152, 138, 126, 110, 81.

FTMS-MALDI:  $m/z$ :  $(M+H)^+$  314.1144

FT-IR: ( $cm^{-1}$ ) 2920, 2344, s, 1819 m, 1702 s, 1255, 1085 s, 1020 s, 797 s.

Molecular formula:  $C_{15}H_{20}ClNO_4$

### Example 2

#### Bioactivity Assays

[0093] Salinosporamide A shows strong activity against human colon cancer cells with an  $IC_{50}$  of 0.011  $\mu\text{g/mL}$  (see Figure 4). The screening on antibacterial or antifungal activity shows no significant activity, see Table 1.

Table 1

Assay ( $\mu\text{g/mL}$ )	$IC_{50}$ of Salinosporamide A,
HCT-116	0.011
<i>Candida albicans</i>	250
<i>Candida albicans</i> (amphotericin B resistant)	NSA*
<i>Staphylococcus aureus</i> (methicillin resistant)	NSA*
<i>Enterococcus faecium</i> (vanomycin resistant)	NSA*

\* NSA = no significant activity

### Example 3

#### Determination of Absolute Stereochemistry


[0094] Crystallization of a compound of structure I from ethyl acetate/*iso*-octane resulted in single, cubic crystals, which diffracted as a monoclinic system P2(1). The unusual high unit-cell volume of 3009 Å hosted four independent molecules in which different conformational positions were observed for the flexible chloroethyl substituent. The assignment of the absolute structure from the diffraction anisotropy of the chlorine substituent resolved the absolute stereochemistry of salinosporamide A as 2R,3S,4R,5S,6S (Figures 16 and 17) with a Flack parameter of 0.01 and an esd of 0.03.

[0095] Although the invention has been described with reference to the above examples, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention. Accordingly, the invention is limited only by the following claims.



What is claimed is:

1. An isolated compound having the structure (I):



(I)

wherein:


$R_1$  to  $R_3$  are each independently  $-H$ , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl,  $-C(O)H$ , acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfuryl;

Each  $R_4$  is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl;

$E_1$  to  $E_4$  are each independently  $-O$ ,  $-NR_5$ , or  $-S$ , wherein  $R_5$  is  $-H$  or  $C_1$ - $C_6$  alkyl; and

X is 0 to 8;


with the proviso that isolated compound does not have the structure of compound (VI).



(VI)


2. The compound of Claim 1, wherein E<sub>1</sub>, E<sub>3</sub>, and E<sub>4</sub> are -O, and E<sub>2</sub> is -NH.
3. The compound of Claim 1, wherein R<sub>1</sub> and R<sub>2</sub> are -H, alkyl, or substituted alkyl, and R<sub>3</sub> is hydroxy or alkoxy.
4. The compound of Claim 1, wherein R<sub>1</sub> is a substituted alkyl.
5. The compound of Claim 4, wherein the substituted alkyl is a halogenated alkyl.
6. The compound of Claim 5, wherein the halogenated alkyl is a chlorinated alkyl.
7. A pharmaceutical composition comprising at least one compound of Claim 1 in a pharmaceutically acceptable carrier therefor.

8. A pharmaceutical composition useful for inhibiting proliferation of hyperproliferative mammalian cells, comprising an effective amount of a pharmaceutically acceptable carrier and a compound of Claim 1 with the proviso that the compound does not have the structure of compound (V).



9. The pharmaceutical composition of Claim 8, further comprising at least one additional anti-neoplastic agent.

10. A method of treating a mammalian cell proliferative disorder, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having the structure (I):



(I)


$R_1$  to  $R_3$  are each independently  $-H$ , alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocyclic, substituted heterocyclic, cycloalkyl, substituted cycloalkyl, alkoxy, substituted alkoxy, thioalkyl, substituted thioalkyl, hydroxy, halogen, amino, amido, carboxyl,  $-C(O)H$ , acyl, oxyacyl, carbamate, sulfonyl, sulfonamide, or sulfonyl;

Each  $R_4$  is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl;

$E_1$  to  $E_4$  are each independently  $-O$ ,  $-NR_5$ , or  $-S$ , wherein  $R_5$  is  $-H$  or  $C_1$ - $C_6$  alkyl; and

$X$  is 0 to 8;

thereby treating a mammalian cell proliferative disorder, with the proviso that the compound does not have the structure of compound (VI).



(VI)

11. The method of Claim 10, wherein the mammalian cell is human.
12. The method of Claim 10, wherein the disorder is characterized by the formation of a neoplasm.
13. The method of Claim 12, wherein the neoplasm is selected from the group consisting of mammary, small-cell lung, non-small-cell lung, colorectal, leukemia, melanoma, pancreatic adenocarcinoma, central nervous system (CNS), ovarian, prostate, sarcoma of soft tissue or bone, head and neck, gastric which includes thyroid and non-Hodgkin's disease, stomach, myeloma, bladder, renal, neuroendocrine which includes thyroid and non-Hodgkin's and Hodgkin's disease neoplasms.
14. The method of Claim 12, wherein the neoplasm is a colorectal neoplasm.

1/17




FIG. 1

## Phylogeny of MAR1

2/17




FIG. 2

3/17

Etoposide (2)




FIG. 3



4/17

## Cytotoxic activity of salinosporamide A (1) and dose response curve

Comp8 (units/ml)


Sample	Wells	Sample #	OD	Mean Value	Ctr. Avg OD	% Survival	Concentration	IC50
Co03	C8	1	0.013	0.013	1.305	0.958	78.125	0.011
Co04	D8	2	0.044	0.044	1.305	3.335	19.534	0.011
Co05	E8	3	0.059	0.059	1.305	4.484	4.883	0.011
Co06	F8	4	0.105	0.105	1.305	8.011	1.221	0.011
Co07	G8	5	0.170	0.170	1.305	12.993	0.305	0.011
Co08	H8	6	0.304	0.304	1.305	23.266	0.076	0.011

Standards (mg/ml)

Sample	Concentration	Back Calc Conc	Wells	OD	Mean OD	% Survival	CV %	Ctr. Avg OD	IC50
Sta03	31.250	Range?	C12	0.413	0.413	31.621	0.0	1.305	0.828
Sta04	7.813	Range?	D12	0.542	0.542	41.510	0.0	1.305	0.828
Sta05	1.953	Range?	E12	0.557	0.557	42.660	0.0	1.305	0.828
Sta06	0.488	Range?	F12	0.760	0.760	58.222	0.0	1.305	0.828
Sta07	0.122	Range?	G12	1.287	1.287	98.620	0.0	1.305	0.828
Sta08	0.031	Range?	H12	1.615	1.615	123.764	0.0	1.305	0.828

Smallest standard value: 0.413

Largest standard value: 1.615



	A	B	C	D	R <sup>2</sup>
◊ Comp.8 (Comp8: Concentration vs % Survival)	2183.255	0.398	8.34e-7	0.073	0.997
◊ Std (Standards: Concentration vs % Survival)	133.236	1.227	0.192	36.119	0.993

FIG. 4

5/17

## Isolation of salinosporamide A (1), separation scheme






FIG. 5

<sup>1</sup>H-NMR of salinosporamide A (1), 300 MHz, d<sub>5</sub>-pyridine

**FIG. 6**

7/17



8/17

HMQC of salinosporamide A (1), 300 MHz, d5-pyridine




FIG. 8

9/17

HMBC of salinosporamide A (1), 300 MHz, d5-pyridine




FIG. 9

10/17




FIG. 10

11/17


NOESY of salinosporamide A (1), 300 MHz, d<sub>5</sub>-pyridine

FIG. 11



12/17

## Mass spectrum (ESI-mode) of salinosporamide A (1)




FIG. 12

13/17




FIG. 13

14/17


UV spectrum (LC-DAD, CH<sub>3</sub>CN:water 2:1) of salinosporamide A (1)

FIG. 14

15/17

Position 16S rDNA	Actinoplanes	Micromon- ospora	Dactylo- sporangium	Catellato- spora	Pillimella	Catenulo- planes	Couchio- planes	Spirilli- planes	Verrucosi- spora	Marinospora
207	U	U	U	U	C	U	U	U	U	A
219	C	C	C	C	U	C	C	C	C	U
279	A	A	A	(AU)	A	A	A	A	A	G
366	A	(A/G)	A	A	A	A	A	A	A	C
467	A	A	(G/A)	A	G	(G/A)	A	A	A	U
468	A	A	A	A	A	A	A	A	A	U
546	G	G	G	G	A	G	G	G	G	A
615	C	(G/C)	C	(U/C)	U	(C/U)	C	C	U	U
1116	C	C	(C/U)	C	C	C	C	C	C	U
1456	A	A	A	A	A	A	A	A	A	G

FIG. 15

16/17




FIG. 16

17/17




FIG. 17

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/19453

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C07D 491/044; A61K 31/407

US CL : 548/453; 514/421

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 548/453; 514/421

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 02/47610 A2 (FENICAL et al) 20 June 2002 (20.06.2002)	1-8

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

13 October 2004 (13.10.2004)

Date of mailing of the international search report

29 NOV 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Fiona T. Powers

Telephone No. 703-308-1235

DEBORAH A. THOMAS  
PARALEGAL SPECIALIST  
GROUP 1300

Form PCT/ISA/210 (second sheet) (January 2004)

